Private equity

PAG buys Chinese biotech firm as SOE reform gathers pace

This acquisition will be the largest private equity investment in China’s biotechnology industry to date.

Asia-focused private equity firm PAG said on Thursday that it has agreed to acquire a controlling interest in Hisun BioRay Bio-pharmaceutical, another example of state-owned enterprise reform in China.

PAG will buy 58% of Hisun BioRay for Rmb3.8 billion $540 million from its parent company, Shanghai Stock Exchange-listed Zhejiang Hisun Pharmaceutical which will continue to retain the remaining 42%.

Headquartered in Taizhou, Zhejiang province, Zhejiang Hisun Pharmaceutical is controlled by China’s government.

As China allows increasing amounts of outside capital into its economy, the country's private equity players are seeing more and more opportunities for investment.

“This transaction marks...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222